AGAP3
Overview
AGAP3 (Arf GAP with GTPase domain, ankyrin repeat, and PH domain 3) is a cytoplasmic GTPase-activating protein. In the context of cancer genomics, AGAP3 has been identified as a fusion partner with BRAF in colorectal cancer, creating an activating kinase fusion that bypasses normal RAS signaling regulation.
Alterations observed in the corpus
- AGAP3-BRAF activating fusion identified in one of two MSS mCRC cases harboring oncogenic BRAF fusions in a 1,122-patient panel sequencing cohort; class of fusion places it as a RAS-independent BRAF activator PMID:29316426.
Cancer types (linked)
- CRC (colorectal cancer): AGAP3-BRAF fusion observed in MSS metastatic colorectal cancer PMID:29316426.
Co-occurrence and mutual exclusivity
- AGAP3-BRAF fusion co-occurs with MSS phenotype in mCRC; found alongside CUL1-BRAF as one of two activating BRAF fusions in the MSS subgroup PMID:29316426.
Therapeutic relevance
- AGAP3-BRAF fusions are predicted to act as RAS-independent BRAF activators, placing them in a class potentially sensitive to BRAF/MEK inhibitor combinations; no direct clinical evidence reported in the corpus to date PMID:29316426.
Open questions
- Whether AGAP3-BRAF fusions predict sensitivity to RAF or MEK inhibitors (analogous to class 2 BRAF mutants) has not been prospectively tested.
Sources
This page was processed by crosslinker on 2026-05-15.